COMMUNIQUÉS West-GlobeNewswire

QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company
30/01/2024
This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers. WEST PALM BEACH, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a [...]
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
30/01/2024
JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will [...]
Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
30/01/2024
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long [...]
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
30/01/2024
Cost Savings Targeted to Reduce Cash Burn by 50% Core Strategy Shifts to Business Development and Distribution Partnerships Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (" [...]
Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman
30/01/2024
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Huxley Health Inc. (“ Huxley ” or the “ Company ”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that [...]
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
30/01/2024
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today [...]
Le KFSH&RC-Madinah reçoit le prestigieux prix 2023 Human Experience Guardian of Excellence de Press Ganey
30/01/2024
RIYAD, Arabie Saoudite, 30 janv. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH&RC) de Médine a remporté le prix 2023 Human Experience Guardian of Excellence décerné par [...]
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
30/01/2024
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc [...]
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
30/01/2024
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the [...]
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
30/01/2024
WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and [...]
Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024
30/01/2024
BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological [...]
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
30/01/2024
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final patient is [...]
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
30/01/2024
FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, [...]
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
30/01/2024
DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic [...]
Central California’s Community Regional Medical Center is the First in the State to Offer Next Generation Robotic Bronchoscopy for Early Diagnosis and Treatment of Lung Cancer
30/01/2024
Innovative new Galaxy System™ deployed as part of commitment to improving the health of residents in the central San Joaquin Valley FRESNO, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- As part of its mission to better the [...]
NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note
30/01/2024
DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced it [...]
Accompany Health Launches to Care for Low-Income Patients with Complex Needs
30/01/2024
New Company Raises $56 Million Series A Funding Round BETHESDA, Md., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Accompany Health , a primary, behavioral, and social care provider for low-income patients with complex needs, [...]
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
30/01/2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
Immutep Quarterly Activities Report Q2 FY24
30/01/2024
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS ≥1%) [...]

Pages